Literature DB >> 19798645

Natalizumab and central nervous system lymphoma: no clear association.

Carmen Bozic, Julia LaGuette, Michael A Panzara, Alfred W Sandrock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19798645     DOI： 10.1002/ana.21835

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  5 in total

Review 1.  Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.

Authors:  Henrik Gensicke; David Leppert; Özgür Yaldizli; Raija L P Lindberg; Matthias Mehling; Ludwig Kappos; Jens Kuhle
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

2.  Cell Trafficking in Chronic Lymphocytic Leukemia.

Authors:  Matthew S Davids; Jan A Burger
Journal:  Open J Hematol       Date:  2012-02-21

Review 3.  Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis.

Authors:  Adnan M Subei; Daniel Ontaneda
Journal:  CNS Drugs       Date:  2015-09       Impact factor: 5.749

Review 4.  Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities.

Authors:  Justin M Honce; Lidia Nagae; Eric Nyberg
Journal:  Mult Scler Int       Date:  2015-09-21

5.  The unexpected finding of a hemangioblastoma on the cerebellum of a patient undergoing treatment with natalizumab for multiple sclerosis.

Authors:  Yara Dadalti Fragoso; Joseph Bruno Bidin Brooks; Mateus Reghin Neto
Journal:  Iran J Neurol       Date:  2017-04-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.